Press Release Archives | Page 4 of 23

Oncotarget News

Response of BRAF-Mutated Spindle Cell Sarcoma to BRAF/MEK Inhibitors

August 14, 2024

This is the first report of spindle cell sarcoma BRAF V600E/S607T double-mutated, responding to a combination of B-Raf and MEK inhibitors.”BUFFALO, NY- August 14, 2024 – A new case... read more

Targeting the multifaceted BRAF in cancer: New directions

Oncotarget

New Directions in Targeting the Multifaceted BRAF in Cancer

August 12, 2024

Here we discuss the diverse forms of BRAF alterations found in human cancers and the strategies to inhibit them in patients harboring cancers of distinct origins.”BUFFALO, NY- August 12,... read more

Chemical complementarity of tumor resident, T-cell receptor CDR3s and renalase-1 correlates with increased melanoma survival

Oncotarget

TCR CDR3s and Renalase-1 Linked to Increased Melanoma Survival

August 8, 2024

These findings indicate that renalase-1 is a potential antigen for TCR recognition in melanoma and could be considered as a target for immunotherapy.”BUFFALO, NY- August 8, 2024 – A new... read more

Oncotarget

Dealing with Runaway Metastatic Disease

August 7, 2024

Metastatic disease remains a major issue in daily practice in oncology because the outcome is still often fatal.”BUFFALO, NY - August 7, 2024 – A new editorial paper was published in... read more

INT-1B3, an LNP formulated miR-193a-3p mimic, promotes anti-tumor immunity by enhancing T cell mediated immune responses via modulation of the tumor microenvironment and induction of immunogenic cell death

Oncotarget

INT-1B3 miR-193a-3p Mimic Boosts T Cell Immunity and Induces Tumor Cell Death

August 5, 2024

INT-1B3 inhibited distant tumor metastasis and significantly prolonged survival.”BUFFALO, NY- August 5, 2024 – A new research paper was published in Oncotarget's Volume 15 on July 12, 2024, entitled, “INT-1B3,... read more

Oncotarget

Prognostic and Therapeutic Insights Into MIF, DDT, and CD74 in Melanoma

July 26, 2024

we present the first study to retrospectively evaluate differential gene expression of MIF, DDT, and relevant pathway markers in regard to clinical outcomes in patients with melanoma.”BUFFALO, NY- July... read more

Oncotarget

Prevalence and Impact of the KIT M541L Variant in Patients With Mastocytosis

July 24, 2024

This study uniquely examines the prevalence and impact of the KIT M541L variant in both adult and pediatric patients with mastocytosis further stratified by disease variant.”BUFFALO, NY- July 24,... read more

Oncotarget

Oncotarget Welcomes New Editorial Board Members

July 22, 2024

Oncotarget is also offering a 50% discount on publication fees until the end of the year.BUFFALO, NY - July 22, 2024 – Oncotarget proudly welcomes new members to our esteemed Editorial... read more

Oncotarget

Improved Efficacy of Pembrolizumab When Combined With sEphB4-HSA in HPV-negative EphrinB2-positive HNSCC

July 22, 2024

Future development for sEphB4-HSA in HNSCC is likely to focus on patients with HPV-negative disease where there is greatest need to improve on the outcomes with pembrolizumab monotherapy.”BUFFALO, NY-... read more

Oncotarget

DDX41 and Its Unique Contribution to Myeloid Leukemogenesis

July 19, 2024

myeloid neoplasms associated with DDX41 variants likely exhibit a unique pathogenesis that diverges from the conventional understanding of myeloid neoplasms.”BUFFALO, NY- July 19, 2024 – A new editorial paper was... read more